Patient-Reported Outcomes Similar With Extended Natalizumab Dosing Interval

(MedPage Today) -- No significant differences emerged in patient-reported outcomes among relapsing-remitting multiple sclerosis (MS) patients who received natalizumab (Tysabri) every 6 weeks (Q6W) versus every 4 weeks (Q4W), an analysis of data...